Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.37 CHF | -4.87% | -0.11% | -4.49% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Mar. 27 | Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.49% | 99.51M | |
+11.18% | 9.08B | |
-15.94% | 4.57B | |
+18.47% | 3.9B | |
+1.89% | 3.69B | |
+28.61% | 2.62B | |
-24.63% | 2.34B | |
-29.37% | 2.14B | |
+2.55% | 1.84B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SANN Stock
- News Santhera Pharmaceuticals Holding AG
- Santhera Pharmaceuticals : Meets Primary Endpoint For Vamorolone In Duchenne Muscular Dystrophy; Shares Soar 50%